铁化在心脏瘤学中的作用
Kai Hou1,2,3,4, Lin Liu5, Zhi-Hui Fang6
1Tianjin Medical University, Tianjin, 300070, China. tjydhoukai@163.com.
Archives of toxicology
|January 5, 2024
概括
新的心脏瘤治疗向铁亡 (细胞死亡),以改善癌症的存活率. 然而,这些疗法可以通过诱导铁亡来伤害心脏,需要研究平衡癌症治疗和心脏保护.
科学领域:
- 心脏瘤学 - 心脏瘤学
- 铁性化 (ferroptosis) 是一种
- 心血管疾病 心血管疾病
- 新形成性疾病 新形成性疾病
背景情况:
- 抗瘤疗法可以延长癌症患者的生存时间,但通常会导致心脏毒性.
- 心脏瘤学是一个新兴的领域,针对癌症患者的心血管疾病.
- 铁亡是一种受调节的细胞死亡,在癌症和心脏病中都起作用.
研究的目的:
- 审查铁质在癌症治疗和心血管疾病中的双重作用.
- 探索抗瘤疗法管理铁亡诱导心脏毒性的挑战.
- 建议未来的研究方向,用于ferroptosis在心脏瘤学.
主要方法:
- 关于瘤和心血管疾病中的铁亡的文献综述.
- 通过抗氧化剂防御途径对铁亡调节的分析.
- 检查诱导铁亡的抗瘤疗法及其心脏毒性作用.
主要成果:
- 瘤细胞利用抗氧化途径来逃避铁亡.
- 抗瘤疗法经常诱导癌细胞中的铁亡,可能导致心脏毒性.
- 抑制ferroptosis的心脏保护剂可能会降低抗瘤功效.
结论:
- 为了有效治疗癌症和保护心脏,平衡铁性至关重要.
- 需要进一步的研究来开发用于调节心脏瘤学中的铁亡的策略.
- 了解铁亡是管理癌症幸存者的心脏毒性的关键.
相关概念视频
Necrosis
4.5K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Electron Transport Chain: Complex I and II
13.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K


